Medpace Announces Upcoming Webinar on Diabetes Clinical Trial Execution
Medpace has scheduled a webinar for November 9, 2026, focused on operational strategies and integrated technology for diabetes clinical trials.
Stocks · News reference
UBS Adjusts Price Target on Medpace to $700 From $673
UBS has updated its price target for Medpace Holdings, Inc., raising it to $700 from $673 while maintaining a Neutral rating.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $670
Analysts Update Price Targets and Ratings for Medpace Holdings, Inc.
Several financial institutions, including UBS, Barclays, and TD Cowen, have updated their price targets and maintained ratings for Medpace Holdings, Inc. following recent performance assessments.
Barclays Maintains Medpace Holdings With Hold Rating, Raises Target Price to $675
Barclays has maintained its hold rating on Medpace Holdings, Inc. and increased its price target to $675.